“Genome Engineering to Advance Regenerative Medicine”
- Science for Admin
Bruce Conklin’s laboratory, established at Gladstone in 1995, studies the mechanisms by which hormonal signals direct the development and function of complex tissues, including those that control the heart. The focus of his research is on the largest known family of receptors for hormones and drugs, the G protein-coupled receptors, which include over 700 human genes. His research focuses on disease-specific stem cells that provide a platform for determining if specific signaling pathways can be used to find new medicines.
His laboratory focuses on human genetics that lead to cardiovascular diseases, such as cardiac arrhythmias and cardiomyopathy. Their model system is induced pluripotent (iPS) cells derived from patients with specific diseases, as well as iPS cells that we engineer to test the role of defined genetic changes on disease. They use human iPS cells to create cardiovascular disease models to better understand basic disease mechanisms and reveal pharmacology approaches (i.e., drugs) to treat those diseases. The Conklin laboratory has a long-standing interest in pharmacology and cellular engineering that allows us to take new approaches to disease modeling to open new avenues for biological investigation and develop novel therapeutic strategies.